Over time, as SGLT2 inhibitors become more readily available, it is anticipated that a larger proportion of patients with CKD will benefit from this therapy, consistent with guideline recommendations for first-line renoprotective pharmacotherapy.8,10. Here, SLC5A2 is linked to chronic kidney disease.